Thompson Siegel & Walmsley LLC Sells 25,635 Shares of Bio-Rad Laboratories, Inc. $BIO

Thompson Siegel & Walmsley LLC trimmed its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 11.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 191,961 shares of the medical research company’s stock after selling 25,635 shares during the period. Bio-Rad Laboratories accounts for about 1.0% of Thompson Siegel & Walmsley LLC’s portfolio, making the stock its 29th biggest holding. Thompson Siegel & Walmsley LLC owned approximately 0.71% of Bio-Rad Laboratories worth $58,162,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Natixis Advisors LLC boosted its holdings in shares of Bio-Rad Laboratories by 67.1% during the third quarter. Natixis Advisors LLC now owns 65,069 shares of the medical research company’s stock worth $18,245,000 after acquiring an additional 26,119 shares during the period. Mangrove Partners IM LLC bought a new position in shares of Bio-Rad Laboratories during the third quarter worth approximately $35,568,000. Gotham Asset Management LLC lifted its holdings in Bio-Rad Laboratories by 41.8% during the 3rd quarter. Gotham Asset Management LLC now owns 124,626 shares of the medical research company’s stock worth $34,944,000 after purchasing an additional 36,763 shares during the last quarter. TD Asset Management Inc lifted its holdings in Bio-Rad Laboratories by 461.0% during the 3rd quarter. TD Asset Management Inc now owns 8,988 shares of the medical research company’s stock worth $2,520,000 after purchasing an additional 7,386 shares during the last quarter. Finally, Magnetar Financial LLC bought a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $2,923,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Trading Up 0.1%

Shares of Bio-Rad Laboratories stock opened at $312.72 on Monday. The firm’s 50 day moving average is $278.57 and its 200 day moving average is $292.03. The firm has a market capitalization of $8.37 billion, a PE ratio of 51.52 and a beta of 1.08. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $343.12. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The firm had revenue of $592.10 million during the quarter, compared to the consensus estimate of $589.91 million. During the same quarter in the previous year, the company posted $2.54 earnings per share. The firm’s revenue was up 1.1% on a year-over-year basis. Equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 9.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. Weiss Ratings downgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Royal Bank Of Canada began coverage on shares of Bio-Rad Laboratories in a research report on Friday, May 15th. They issued an “outperform” rating and a $320.00 price target for the company. Finally, Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories has an average rating of “Hold” and a consensus price target of $303.33.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.